N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced two operational updates.
Granting of further US patent
The University of Queensland has informed the Company that it has been notified by the US patent attorney of the granting of its further patent application in relation to Nuvec® in the United States.
N4 Pharma has licensed the exclusive worldwide rights to Nuvec® from the University of Queensland for therapeutic uses in humans and animals.
This granted patent in the US is for the composition of matter of the nanoparticle itself and will sit alongside the first US patent grant announced on 31 January 2022, which concerned how the nanoparticle is made using a broad description of the manufacturing process used by the Company.
Board Change
The Company announces that John Chiplin, currently Non-Executive Chairman, is retiring from the Board for personal reasons. Chris Britten, currently a Non-Executive Director of the Company, will assume the role of Non-Executive Chairman of N4 Pharma with effect from 1 August 2023.
The Company will initiate a search process to identify an additional Non-Executive Director and will provide an update as and when appropriate.
Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:
“We are delighted to receive notification of this further patent grant for our licensed patent in this critical and influential market.
“The granting of this patent now means the patents in the US are on equal terms to those granted in other territories for both the particle itself and how it is made.
“On behalf of the Board, I would like to thank John for his contributions as Chairman of the Company over the last few years and we wish him all the best for the future.”
